alzheimers news-these three alzheimers treatment drugs will be available soon in clinical research

ALZHEIMERS NEWS-THESE THREE ALZHEIMERS TREATMENT DRUGS WILL BE AVAILABLE SOON IN CLINCAL STUDIES

aduhelm (aducanumab) is made by biogen
it is now approved for use in early alzheimers disease or mild cognitive impairment due to alzheimers disease
it will be available at probably neurologists or other alzheimers care doctors sometime this year or next year
it will probably be covered by insurance but how much out of pocket costs there will be to the patient is not known

lecanemab is made by biogen who makes my drug
it works similar to aduhelm (aducanumab)
it probably is more effective than aduhelm
it just got approved by the fda for breakthrough status which means it can get on a quick approval tract like aduhelm did
it also will be starting a new study looking at patients with prealzheimers ie no symptoms but with positive scan

donanemab is made by lilly
it also works similar to aduhelm
it also is probably more effective than aduhelm
it also just got approved by the fda for breakthrough status putting it also on a quick approval tract like aduhelm was on 

so how can use access them

aduhelm will soon be available across the us in the private world
biogen is also having to do a 9 year clinical study that is being required by the fda 
that study will probably be available on clinicialtrials.gov when its available for enrollment
the advantage of the study is there is no cost
eg at the end of my present study i will have received 31 doses of aduhelm
that would cost me almost $150,000
i will have had over 6 mris and 3 amyvid pet scans and 2 tau protein pet scans plus all the other labs and ekgs and neurology visits and memory testing that is required
plus
all that was done on me when i got my 18 months of placebo

this drug aduhelm will be the one that you and your love one can access first
you have to be early in the disease to qualify for it
if its given too late it doesnt help 
we are talking about a 22% slowing of cognitive decline for all that effort
will it help 
time will tell

lecanemab will work better than aduhelm
it attacks the amyloid differently than aduhelm
its also known as ban2401
some openings are available for the ongoing studies but many sites are closed
eg ucla is full in its lecanemab study 

remember use clinicaltrials.gov to track the lecanemab studies
it will probably be 3-5 years before it can get approval

donanemab is probably closer to getting approval than lecanemab
it is probably 2-5 years before it can get approval
it has about a 35% slowing of cognitive decline
it will probably bump aduhelm out of the market some when it gets there
it only is given for 2 years then its discontinued

all three remove the amyloid from the brain

whichever wins the war on how well it works will be the one thats used most

you can also track these drugs online

aduhelm
aduhelm website
this link above has the package insert on the drug
biogen website

lecanemab
article with multiple links
biogen lecanemab link
link to clinical trials of lecanemab in prealzheimers patients

donanemab
lilly donanemab link

link to articles on all three drugs

also go to the clinicaltrials.gov link and type in the drug your are interested in 
it will give you links to all the studies being done on it

if you want one of these drugs for you or a loved ones you will need to be proactive to get them
you also need to understand what they will do or wont do to help 

these studies wont come looking for you 
you have to search for them

the advantage of the studies is that there is no cost it just takes some of your time
in my case it was worth it

will these drugs really help 
maybe 
maybe not

the organicgreen doctor